Article

Ending transmission of SARS-CoV-2: sterilizing immunity using an intranasal subunit vaccine

2022-07-15

Abstract excerpt

<h4>ABSTRACT</h4> Immunization programs against SARS-CoV-2 with commercial intramuscular (IM) vaccines prevent disease but not infections. The continued evolution of variants of concern (VOC) like Delta and Omicron has increased infections even in countries with high vaccination coverage. This is due to commercial vaccines being unable to prevent viral infection in the upper airways and exclusively targeting the...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 29bac63f-0e42-5d51-b91d-2a8ef59cf74c
DOI: 10.1101/2022.07.14.500068

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Ending transmission of SARS-CoV-2: sterilizing immunity using an intranasal subunit vaccineDOI 10.1101/2022.07.14.500068Read

Protection of Hamsters Challenged with SARS-CoV-2 after Two Doses of MVC-COV1901 Vaccine Followed by a Single Intranasal Booster with Nanoemulsion Adjuvanted S-2P VaccineSemantic proximity Read

An intranasal OMV-based vaccine induces high mucosal and systemic protecting immunity against a SARS-CoV-2 infectionSemantic proximity Read

Intranasal Nanoemulsion Adjuvanted S-2P Vaccine Demonstrates Protection in Hamsters and Induces Systemic, Cell-Mediated and Mucosal Immunity in MiceSemantic proximity Read

Single-dose respiratory mucosal delivery of next-generation viral-vectored COVID-19 vaccine provides robust protection against both ancestral and variant strains of SARS-CoV-2Semantic proximity Read

Intranasal SARS-CoV-2 Omicron Variant Vaccines Elicit Humoral and Cellular Mucosal Immunity in MiceSemantic proximity Read

Enhanced mucosal SARS-CoV-2 immunity after heterologous intramuscular mRNA prime/intranasal protein boost vaccination with a combination adjuvantSemantic proximity Read

Intranasal administration of a VLP-based vaccine against COVID-19 induces neutralizing antibodies against SARS-CoV-2 and Variants of ConcernsSemantic proximity Read

Durable protection against SARS-CoV-2 Omicron induced by an adjuvanted subunit vaccineSemantic proximity Read

Mucosal immunity against SARS-CoV-2 variants of concern including Omicron following vaccinationSemantic proximity Read

Single intranasal immunization with attenuated Wuhan-like SARS-CoV-2 provides highly effective cross-protection against Delta and Omicron VOCsSemantic proximity Read

Challenges and developments in universal vaccine design against SARS-CoV-2 variantsSemantic proximity Read

A next-generation intranasal trivalent MMS vaccine induces durable and broad protection against SARS-CoV-2 variants of concernSemantic proximity Read